Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial by Li, Kezhen, Prof, Chen, Jing, MD, Hu, Yingjie, MD, Wang, Yan-Zhou, Prof, Shen, Yuanming, Prof, Chen, Gang, Prof, Peng, Wenju, MD, Fang, Zixuan, MD, Xia, Bairong, Prof, Chen, Xiaojun, Prof, Song, Kun, Prof, Wang, Yingmei, Prof, Zou, Dongling, Prof, Wang, Yan-Chun, PhD, Han, Yingyan, PhD, Feng, Xue, MD, Yuan, Jing, PhD, Guo, Shuaiqingying, BM, Meng, Xiaolin, BM, Feng, Chenzhao, MD, Chen, Yin, Prof, Yang, Jie, Prof, Fan, Junpeng, PhD, Wang, Jianliu, Prof, Ai, Jihui, Prof, Ma, Ding, Prof, Sun, Chaoyang, Prof

Get full text

Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial by Peng, Zikun, MD, Li, Huayi, MD, Gao, Yunong, MD, Sun, Li, MD, Jiang, Jie, MD, Xia, Bairong, MD, Huang, Yi, MD, Zhang, Yu, MD, Xia, Yu, PhD, Zhang, Yuxin, MD, Shen, Yiyang, BS, Huang, Bowen, BS, Nie, Jiayu, BS, Chen, Xinrong, BS, Liu, Xingyu, MD, Feng, Cui, MD, Li, Zhen, MD, Zhang, Wei, MD, Tao, Kangjia, MS, Zhang, Qiuxue, PhD, Duan, Shican, BS, Chen, Yaheng, MD, Chen, Yeshan, MD, Wang, Wei, MD, Zheng, Hong, MD, Lu, Yudong, PhD, Liu, Yi, MD, Wang, Limei, MD, Qi, Wencai, MD, He, Yang, MD, Tian, Yan, MD, Li, Guiling, Prof, Ma, Ding, Prof, Gao, Qinglei, Prof

Get full text